+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Wet Age - Related Macular Degeneration (Wet - AMD) - Pipeline Insight, 2021

  • ID: 4989309
  • Clinical Trials
  • May 2021
  • Region: Global
  • 190 pages
  • DelveInsight

FEATURED COMPANIES

  • AiViva BioPharma
  • Bioeq GmbH
  • Feramda
  • Isarna Therapeutics
  • Opthea Limited
  • RemeGen
  • MORE
This “Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Wet Age-Related Macular Degeneration (Wet-AMD) Understanding


Wet Age-Related Macular Degeneration (Wet-AMD): Overview


Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10-20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type.

Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision.

The complaints of a patient with wet AMD may vary from metamorphopsia, central or paracentral scotoma, to a sudden, nonspecific reduction in central vision. Common symptoms of wet AMD include: Distortion of straight lines (metamorphopsia), a blind spot or hole in one's vision (scotoma), difficulty with adaptation to the dark.

Age-related macular degeneration is defined by fundus examination, but the diagnosis of AMD is typically based on age, clinical findings through various tests like Color fundus photography, Fluorescein angiography and/or Optical coherence tomography. Color photography and fluorescein angiography are done when findings suggest wet AMD. A simple test for daily monitoring of vision in patients with AMD is the Amsler grid. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches for Wet Age-Related Macular Degeneration (Wet-AMD).

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters


This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs


SOK583A1: Sandoz

Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz. In May 2021, Sandoz announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT - a clinical Phase III confirmatory efficacy and safety study.

SB15: Samsung Bioepis

SB15 is being developed as a biosimilar to the reference product Eylea (aflibercept) - an anti-VEGF drug.

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Samsung Bioepis. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the US, Canada, Europe, Japan, and Australia.

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment


This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:


Major Players working on Wet Age-Related Macular Degeneration (Wet-AMD)


There are approx. 70+ key companies which are developing the Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.

Phases


This report covers around 70+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights

  • Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Scenario and Emerging Therapies:

  • How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
  • How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration (Wet-AMD)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Sandoz
  • Sam Chun Dang Pharm
  • Samsung Bioepis
  • Opthea Limited
  • Luye Pharma
  • Shanghai Henlius Biotech
  • Generium Pharmaceuticals
  • Bioeq GmbH
  • Roche
  • Chong Kun Dang Pharmaceutical
  • Outlook Therapeutics
  • Kodiak Sciences
  • Amgen
  • Qilu Pharmaceuticals
  • Xbrane Biopharma
  • Regenxbio
  • Formycon
  • Dobecure
  • Gemini Therapeutics
  • Isarna Therapeutics
  • AngioLab Inc
  • Alkahest
  • Tyrogenex
  • IVERIC bio (formerly Ophthotech Corporation)
  • Tasly Pharmaceutical Group
  • Ribomic
  • Innovent Biologics
  • Gemini Therapeutics
  • GrayBug Vision
  • Curacle
  • Quark Pharmaceuticals
  • Bio-Thera Solutions
  • RemeGen
  • Sinocelltech
  • PanOptica
  • Clearside Biomedical
  • AsclepiX Therapeutics
  • Feramda
  • AiViva BioPharma
  • Unity Biotechnology
  • Kyowa Kirin
  • Ocular Therapeutix
  • Janssen Research & Development
  • Huabo Biopharm
  • EyePoint Pharmaceuticals
  • Shanghai Biomabs Pharmaceutical
  • Ashvattha Therapeutics
  • Samjin Pharm
  • Akari Therapeutics
  • Eyevensys
  • PharmAbcine
  • Neurophth Therapeutics
  • Ocugen

Key Products

  • SOK583A1
  • SCD411
  • SB15
  • OPT-302
  • LY09004
  • HLX04-O
  • GNR-067
  • FYB203
  • Faricimab
  • CKD-701
  • ONS-5010
  • KSI-301
  • ABP 938
  • BCD 300
  • Xlucane
  • RGX-314
  • FYB201
  • Etamsylate
  • GEM-103
  • ISTH0036
  • ALS-L1023
  • AKST4290
  • Vorolanib (X-82)
  • Zimura
  • Sanhuangjingshimingwan
  • RBM-007
  • IBI302
  • GEM103
  • GB-102
  • CU03
  • PF-04523655
  • BAT5906
  • RC 28 E
  • SCT510A
  • PAN 90806
  • CLS-AX
  • AXT107
  • AS101
  • AIV007
  • UBX1325
  • KHK4951
  • OTX-TKI
  • AAVCAGsCD59
  • HB002.1M
  • EYP-1901
  • CMAB818
  • D-4517
  • SJP1803/1804
  • Nomacopan
  • EYS609
  • EYS809
  • PMC-309
  • PMC-403
  • NFS-10
  • OCU 200

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AiViva BioPharma
  • Bioeq GmbH
  • Feramda
  • Isarna Therapeutics
  • Opthea Limited
  • RemeGen
  • MORE
Introduction

Executive Summary

Wet Age-Related Macular Degeneration (Wet-AMD): Overview
  • Structure
  • Mechanism of Action
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Wet Age-Related Macular Degeneration (Wet-AMD)- Analytical Perspective

In-depth Commercial Assessment
  • Wet Age-Related Macular Degeneration (Wet-AMD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Wet Age-Related Macular Degeneration (Wet-AMD) Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
SOK583A1: Sandoz
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
ISTH0036: Isarna Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
UBX1325: Unity Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
EYS809: Eyevensys
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies

Wet Age-Related Macular Degeneration (Wet-AMD) Key Products

Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs

Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers

Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion

Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views

Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies

Appendix

List of Tables
Table 1 Total Products for Wet Age-Related Macular Degeneration (Wet-AMD)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Wet Age-Related Macular Degeneration (Wet-AMD)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AiViva BioPharma
  • Akari Therapeutics
  • Alkahest
  • Amgen
  • AngioLab Inc
  • AsclepiX Therapeutics
  • Ashvattha Therapeutics
  • Bio-Thera Solutions
  • Bioeq GmbH
  • Chong Kun Dang Pharmaceutical
  • Clearside Biomedical
  • Curacle
  • Dobecure
  • EyePoint Pharmaceuticals
  • Eyevensys
  • Feramda
  • Formycon
  • Gemini Therapeutics
  • Generium Pharmaceuticals
  • GrayBug Vision
  • Huabo Biopharm
  • Innovent Biologics
  • Isarna Therapeutics
  • IVERIC bio (formerly Ophthotech Corporation)
  • Janssen Research & Development
  • Kodiak Sciences
  • Kyowa Kirin
  • Luye Pharma
  • Neurophth Therapeutics
  • Ocugen
  • Ocular Therapeutix
  • Opthea Limited
  • Outlook Therapeutics
  • PanOptica
  • PharmAbcine
  • Qilu Pharmaceuticals
  • Quark Pharmaceuticals
  • Regenxbio
  • RemeGen
  • Ribomic
  • Roche
  • Sam Chun Dang Pharm
  • Samjin Pharm
  • Samsung Bioepis
  • Sandoz
  • Shanghai Biomabs Pharmaceutical
  • Shanghai Henlius Biotech
  • Sinocelltech
  • Tasly Pharmaceutical Group
  • Tyrogenex
  • Unity Biotechnology
  • Xbrane Biopharma
Note: Product cover images may vary from those shown
Adroll
adroll